ArticleACR open rheumatology2026
Serum Endothelin-1 Is Associated With Interstitial Lung Disease in Idiopathic Inflammatory Myopathy.
Article in ACR open rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivePrevious studies by our research group demonstrated that interstitial lung disease (ILD) associated with idiopathic inflammatory myopathy (IIM) correlates with endothelial cell injury and neutrophil extracellular trap (NETs) formation. This study aimed to investigate the clinical relevance of serum endothelin-1 (ET-1) and NET markers, such as cell-free DNA (cfDNA), in IIM-associated ILD (IIM-ILD).
methodsPeripheral blood samples were collected from 60 patients with IIM (44 with dermatomyositis and 16 with polymyositis) and 20 healthy controls. Among the patients with IIM, 33 were diagnosed with ILD. Serum ET-1 and cfDNA levels were measured, and differences in ET-1 levels across groups, correlations between ET-1 and cfDNA, and diagnostic performance via logistic regression models and receiver operating characteristic (ROC) curves were analyzed.
resultsSerum ET-1 levels were significantly elevated in patients with IIM compared to healthy controls (10.89 ± 3.49 pg/mL vs 2.09 ± 0.56 pg/mL, P < 0.0001). The subgroup with IIM-ILD exhibited a 36.3% increase in ET-1 levels compared to the subgroup with IIM without ILD (12.17 ± 3.67 pg/mL vs 9.34 ± 2.53 pg/mL, P = 0.0012), with a positive correlation between ET-1 and cfDNA (r = 0.374, P = 0.003). Multivariate analysis identified ET-1 as an independent risk factor for ILD (odds ratio 1.442, 95% confidence interval 1.082-1.923). A combined model incorporating ET-1, albumin-globulin ratio, lactate dehydrogenase, and complement C4 achieved an area under the ROC curve of 0.888 (sensitivity 78.8% and specificity 88.9%).
conclusionSerum ET-1 levels were elevated in patients with IIM, particularly in those with ILD, suggesting its potential role in the pathogenesis and progression of IIM-ILD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.